Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kazia Therapeutics reported that VP, Finance and Controller Jeffrey Bonacorda received a grant of employee stock options over 150,000 ADSs. These options have an exercise price of $6.78 per ADS, set by reference to the Nasdaq closing price on January 8, 2026.
One-third of the options vest on January 8, 2027, with the remaining two-thirds vesting in equal annual tranches on each anniversary of that date. The options were granted for no cash consideration, are held directly, and will expire on January 8, 2029, if not exercised.
Positive
- None.
Negative
- None.
Insights
Routine option grant to finance executive, compensation-related and non-market.
The filing shows 150,000 stock options granted to VP, Finance and Controller Jeffrey Bonacorda at an exercise price of $6.78 per ADS. This is a board and Remuneration Committee–approved compensation award, not an open-market purchase or sale.
The options vest over three years starting January 8, 2027 and expire on January 8, 2029. Since this is a standard equity incentive grant with no associated sale, it is generally viewed as a routine compensation event rather than a directional signal about the company’s shares.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bonacorda Jeffrey
Role
VP, Finance and Controller
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 150,000 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 150,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 150,000 options
Exercise price: $6.78 per ADS
Vesting start date: January 8, 2027
+4 more
7 metrics
Options granted
150,000 options
Employee Stock Option grant over ADSs to VP, Finance and Controller
Exercise price
$6.78 per ADS
Set by reference to Nasdaq closing price on January 8, 2026
Vesting start date
January 8, 2027
One-third of options vest on this Commencement Date
Remaining vesting period
Two annual tranches
Remaining two-thirds vest on anniversaries of January 8, 2027
Expiration date
January 8, 2029
Options expire if not exercised by this date
Total derivative holdings after grant
150,000 options
Total shares following transaction for this option award
Grant consideration
$0.00
Options were granted for no cash consideration
Key Terms
ADSs, Remuneration Committee, exercise price, vesting, +2 more
6 terms
ADSs financial
"Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee"
Remuneration Committee financial
"award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026"
A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.
exercise price financial
"at an exercise price of $6.78 per ADS, which was set by reference to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"One-third of the options vest on January 8, 2027 and the remaining two-thirds vest in equal yearly tranches"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Commencement Date financial
"One-third of the options vest on January 8, 2027 (the "Commencement Date")"
options were granted for no consideration financial
"The options were granted for no consideration and expire on January 8, 2029"
FAQ
What did Kazia Therapeutics (KZIA) disclose about Jeffrey Bonacorda in this Form 4?
Kazia Therapeutics disclosed that VP, Finance and Controller Jeffrey Bonacorda received a grant of 150,000 employee stock options over ADSs. The award is a board and Remuneration Committee–approved equity compensation grant, not an open-market transaction involving cash purchases or sales of shares.
How many stock options did Jeffrey Bonacorda receive from Kazia Therapeutics (KZIA)?
Jeffrey Bonacorda received 150,000 employee stock options over Kazia Therapeutics ADSs. Following this grant, his derivative holdings reported in this filing total 150,000 options, reflecting the full amount of this new award as part of his equity-based compensation package.
What is the exercise price of Jeffrey Bonacorda’s options at Kazia Therapeutics (KZIA)?
The employee stock options granted to Jeffrey Bonacorda have an exercise price of $6.78 per ADS. This price was set by reference to the closing price of Kazia Therapeutics’ ADSs on Nasdaq on January 8, 2026, aligning the grant with the market level that day.
When do Jeffrey Bonacorda’s Kazia Therapeutics (KZIA) options vest?
One-third of the options vest on January 8, 2027, known as the Commencement Date. The remaining two-thirds vest in equal yearly tranches on each anniversary of that date, creating a three-year vesting schedule designed to encourage ongoing retention and performance.
When do Jeffrey Bonacorda’s stock options at Kazia Therapeutics (KZIA) expire?
The employee stock options granted to Jeffrey Bonacorda expire on January 8, 2029, if they are not exercised before that date. After expiration, any unexercised options will be forfeited, meaning they can no longer be converted into ADSs.
Did Jeffrey Bonacorda pay cash for the Kazia Therapeutics (KZIA) option grant?
No, the filing states the options were granted for no consideration, meaning Jeffrey Bonacorda did not pay cash to receive them. Any future value would come only if Kazia Therapeutics’ ADS price exceeds the $6.78 exercise price and the options are exercised.